| Document |
Document Title |
|
WO/2019/075136A1 |
The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
|
|
WO/2019/070236A1 |
The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein ...
|
|
WO/2019/068177A1 |
This application relates to a method of detecting negatively charged phosphate- containing membranes and membrane components, such as in cell membranes or artificial lipid vesicles, and its use, for example, in detecting apoptosis and ba...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/040992A1 |
The invention relates to oleoyl-lysophosphatidylinositol (oleoyl-LPI) and new synthetic derivatives thereof and uses thereof, and to pharmaceutical compositions comprising such compounds. The invention provides activators and/or up-regul...
|
|
WO/2019/045436A1 |
Disclosed are: an intermediate capable of high-purity synthesis of gadobutrol which can be used as an MRI contrast agent; and a gadobutrol production method using same. The gadobutrol intermediate is represented by Chemical Formula 2 in ...
|
|
WO/2019/045581A1 |
New 5-aminotetrazole derivatives with antimicrobial and antifungal activity are disclosed.
|
|
WO/2019/040585A1 |
Provided herein are improved methods of producing a derivative of PF1022A, for example a compound of Formula I: Formula I wherein R1 and R2 are each independently hydrogen or nitro, and at least one of R1 and R2 is nitro. In some embodim...
|
|
WO/2019/034729A1 |
The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, ...
|
|
WO/2019/025540A1 |
The invention relates to 3-acyl-benzamides of formula (I) as herbicides. In formula (I) X, Y, Z and Rx represent radicals such as alkyl, cycloalkyl and halogen.
|
|
WO/2019/018186A1 |
The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to composition...
|
|
WO/2019/016377A1 |
The present invention relates to novel lipophilic macrocyclic ligands, the complexes thereof, in particular radioactive complexes, and the uses of same in medical imaging and/or in therapy, in particular in interventional radiology.
|
|
WO/2019/016385A1 |
The present invention relates to benzamide compounds of the formula (I) and the N-oxides and salts thereof and to compositions comprising the same. The variables are as defined in the claims and the description. The invention also relate...
|
|
WO/2018/234371A1 |
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and the other variables are as defined in the claims and the description. The invention further relates to a composition comprising such compound and ...
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/228857A1 |
The invention relates to novel laser markable compositions comprising developing agent precursors according to formula (I).
|
|
WO/2018/222778A1 |
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
|
|
WO/2018/219935A1 |
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4 (formulae (Q1), (Q2), (Q3), (Q4)); and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, both R4 and R5 are hydrogen, R1, R3 and ...
|
|
WO/2018/219936A1 |
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, R5 is hydrogen, R1, R3, R4 and R6 represent groups such as hydrogen, halog...
|
|
WO/2018/215070A1 |
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...
|
|
WO/2018/215610A1 |
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...
|
|
WO/2018/216823A1 |
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...
|
|
WO/2018/209366A2 |
A method of producing K2DNABT wherein a biztetrazole intermediate is nitrated using a nitrating agent selected from the following: dinitronium disulphate; a mixture of nitric acid and sulfuric acid; a mixture of nitric acid and phosphoro...
|
|
WO/2018/202535A1 |
Substituted benzoyl amides and their use as herbicides. The invention relates to benzoyl amides of general formula (I) as herbicides. In formula (I) X, R and Ra represent radicals such as alkyl, cycloalkyl and halogen. Q is a five-member...
|
|
WO/2018/204532A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2018/189340A1 |
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...
|
|
WO/2018/158592A1 |
A process for preparing a tetra-substituted aminobiphenol macrocyclic ligand having the structure (I), comprising the step of treating a precursor compound having the structure (II) with a compound having the structure R6-L where L repre...
|
|
WO/2018/158131A1 |
The invention relates to a method for the production of fluoroalkyl nitriles and of the corresponding fluoroalkyl tetrazoles, proceeding from fluorinated carboxylic acid amides.
|
|
WO/2018/140339A1 |
Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Y is defined herein. Also disclosed are methods for reducing the glycem...
|
|
WO/2018/120923A1 |
Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presenc...
|
|
WO/2018/122325A1 |
The present invention pertains to a system of collaborative modifiers that are assembled into a multi molecule complex in vivo within a cell using bioorthogonal chemical reactions. The system of the invention is composed of multiple bind...
|
|
WO/2018/114541A2 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2018/114783A1 |
The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufa...
|
|
WO/2018/110669A1 |
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and meth...
|
|
WO/2018/108780A1 |
The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with the paramagnetic metal ions and the use thereof as contrast agents, particularly suitable for M...
|
|
WO/2018/097318A1 |
The present invention provides a tetrazolinone represented by formula (I) and a pest control agent comprising the same, and their use thereof. Formula (I) [wherein, W1 represents an oxygen atom or a sulfur atom; W2 represents a hydrogen ...
|
|
WO/2018/096082A1 |
The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
|
|
WO/2018/097431A1 |
The present invention provides a composition for protecting the skin from heavy metals and formaldehyde, comprising at least one selected from the group consisting of trientine or trientine derivative of Formula (1), cyclen or cyclen der...
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/081047A1 |
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: (Formula (I)) wherein R1, R2, R3, A, W, L, R...
|
|
WO/2018/073157A1 |
The invention relates to a method for producing 3-alkylsulfanyl-2-chloro-N-(1-alkyl-1H-tetrazol-5-yl)-4-trif
luoromethyl-benzamides of formula (I). In said formula, the substituents R1 and R2 represent residues such as alkyl and substitu...
|
|
WO/2018/059914A1 |
A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and...
|
|
WO/2018/055133A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2018/056546A1 |
Provided are: a compound represented by a particular chemical formula; a core shell dye which comprises a core comprising the compound, and a shell covering the core; a photosensitive resin composition comprising the core-shell dye; and ...
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/051197A1 |
The present invention relates to the preparation of a series of chiral DOTA, D03A, D02A, DO1A, cyclen and their metal complexes, which display properties superior to those of previous DOTA- based compounds, and hence are potentially valu...
|
|
WO/2018/040065A1 |
Provided are crystal forms A, B, D, E, F, G, and H of valsartan disodium salt, and a preparation method therefor.
|
|
WO/2017/171657A9 |
A device and a method for detection of an acryloyl group in a sample are provided. The device comprises a first device coupleable to a second device having a transceiver and a camera for detection of an acryloyl group in a sample, the fi...
|
|
WO/2018/029150A1 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
|
WO/2018/014140A1 |
Disclosed herein is a method for multimodal imaging during a medical procedure using magnetic resonance imaging (MRI) and Raman optical imaging which involves administering an MRI imaging contrast agent that a chemical structure having c...
|
